Azacitidine with CHOP for newly diagnosed TFH nodal T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies azacitidine plus standard CHOP chemotherapy for newly diagnosed nodal T-cell lymphoma that has a specific “TFH” subtype. It aims to improve treatment control for people with this lymphoma type by testing a new combination in an early-phase study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed nodal T-cell lymphoma with the TFH subtype (including angioimmunoblastic, follicular helper, or follicular-helper–type forms).
- You are between 20 and 85 years old.
- You can do daily activities fairly well (ECOG score 0–2).
- Your heart, kidney, and liver test results are good enough for chemotherapy.
- Your blood counts are high enough (neutrophils and platelets above required minimums).
- You can follow the study schedule and agree to sign consent; if you can become pregnant or make someone pregnant, you must use reliable birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding chidamide to a combination chemotherapy plan (azacitidine, liposomal mitoxantrone, and prednisone) works better for people newly diagnosed with nodal T-follicular helper (TFH) cell lymphoma. It’s testing a treatment strategy after diagnosis to improve disease control and outcomes.
This trial tests adding an oral targeted drug called ruxolitinib to the standard CHOP chemotherapy for people newly diagnosed with a rare type of lymphoma. The goal is to see if this combination is safe and works well.
This trial tests a new drug (tucidinostat) added to standard chemotherapy (CHOP) for people newly diagnosed with a specific type of lymphoma called PTCL-TFH. It aims to see if the combination works better than standard treatment alone.
This Phase 3 study compares two chemo options—CHOP alone versus CHOP plus AC—for people whose peripheral T-cell lymphoma is the “T-follicular helper” type (PTCL-TFH). The goal is to see which treatment works better for people who have not received lymphoma treatment yet.
This trial tests a new drug, linperlisib, combined with standard chemotherapy (CHOP) for people newly diagnosed with a rare type of T-cell lymphoma (nTFHL) who plan to have a stem cell transplant. It aims to see if this combination is safe and effective.
This trial tests a combination of belinostat (a targeted drug) plus either azacitidine or pralatrexate for people with relapsed or refractory T-cell lymphoma. The goal is to find a new treatment option when previous therapies have stopped working.
Hear when a new T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.